Skip to main content

A step closer to a cure: Gilead seeks FDA OK of oral attack on hepatitis C

Gilead Sciences Inc. asked U.S. regulators Monday to approve what could be the first oral treatment for most hepatitis C patients...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.